Individualizable dosage form

• US 20100068235A1
• Filed: 09/16/2008
• Published: 03/18/2010
• Est. Priority Date: 09/16/2008
• Status: Abandoned Application

• Current Assignee: The Invention Science Fund I, L.L.C. (Intellectual Ventures LLC)
• Original Assignee: Searete LLC A Limited Liability Corporation of The State of Delaware
• Inventors: Ishikawa, Muriel Y., Boyden, Edward S., Wood, Lowell L. JR., Rivet, Dennis J., Hyde, Roderick A., Sweeney, Elizabeth A., Wood, Victoria Y.H., Bangera, Mahalaxmi Gita
• Application Number:
  US12/284,015
• Publication Number:
  US 20100068235A1
• Time in Patent Office: Days
• US Class Current: 424/401
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/28 Dragees; Coated pills or tablets , e.g. with film or compression coating A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209
• CPC Class Codes: G16H 20/13 delivered from dispensers

Abstract

Provided embodiments include a final dosage form, an article of manufacture, and a method. A final dosage form for delivering a medicament to an animal is provided. The final dosage form includes an outer layer. The final dosage form also includes a release element configured in a first medicament-release state and modifiable to a second medicament-release state upon an ex vivo exposure to a stimulus. The final dosage form further includes a chamber at least substantially within the outer layer and configured to carry the medicament. The final dosage form further includes a containment element configured to retain the medicament within the final dosage form until the dosage form is administered to the animal. The final dosage form includes the medicament. The final dosage form may include an indicator element configured to indicate an exposure of the release element to the stimulus.

Claims

1. A final dosage form for delivering a medicament to an animal, the final dosage form comprising:

an outer layer;

a release element configured in a first medicament-release state and modifiable to a second medicament-release state upon an ex vivo exposure to a stimulus;

a chamber at least substantially within the outer layer and configured to carry the medicament;

the medicament; and

a containment element configured to retain the medicament within the final dosage form until the dosage form is administered to the animal.

2. The final dosage form of claim 1, wherein the containment element configured to retain the medicament within the final dosage form until the dosage form is administered to the animal includes:

at least a portion of the outer layer configured to retain the medicament within the final dosage form until the dosage form is administered to the animal.

3. The final dosage form of claim 1, wherein the release element and the containment element are an at least a substantially same structure.

4. The final dosage form of claim 1, wherein release element and the containment element are at least substantially different structures.

5. The final dosage form of claim 1, wherein the containment element configured to retain the medicament within the final dosage form until the dosage form is administered to the animal includes:

a containment element configured to prevent a release of the medicament from the final dosage form until the final dosage form is introduced into the animal.

6. The final dosage form of claim 1, wherein the containment element configured to retain the medicament within the final dosage form until the dosage form is administered to the animal includes:

a containment element formed by at least a portion of the outer layer and configured to retain the medicament within the final dosage form until the dosage form is administered to the animal.

7. The final dosage form of claim 1, wherein the containment element configured to retain the medicament within the final dosage form until the dosage form is administered to the animal includes:

a containment element formed by at least a portion of the release element and configured to retain the medicament within the final dosage form until the dosage form is administered to the animal.

8. The final dosage form of claim 1, wherein the containment element configured to retain the medicament within the final dosage form until the dosage form is administered to the animal includes:

a containment element formed by at least a portion of the release element and by at least a portion of the outer layer, and configured to retain the medicament within the final dosage form until the dosage form is administered to the animal.

9. The final dosage form of claim 1, wherein the containment element configured to retain the medicament within the final dosage form until the dosage form is administered to the animal includes:

a containment layer configured to encapsulate the medicament within the final dosage form until the final dosage form is administered to the animal.

10. The final dosage form of claim 1, wherein the containment element configured to retain the medicament within the final dosage form until the dosage form is administered to the animal includes:

a containment envelope configured to retain the medicament within the final dosage form until the dosage form is administered to the animal.

11. The final dosage form of claim 1, wherein the containment element configured to retain the medicament within the final dosage form until the dosage form is administered to the animal includes:

an excipient or an admixture with the medicament and configured to retain the medicament within the final dosage form until the dosage form is administered to the animal.

12. The final dosage form of claim 1, wherein the medicament includes at least one of an agent, treatment agent, drug, prodrug, therapeutic, nutraceutical, medication, vitamin, nutritional supplement, medicine, remedy, medicinal substance, or cosmetic.

13. The final dosage form of claim 1, wherein the medicament includes a first component of a medicament of and a second component of the medicament.

14. The final dosage form of claim 1, wherein the medicament includes at least one prodrug and an activating-enzyme of the prodrug.

15. The final dosage form of claim 1, wherein the chamber at least substantially within the outer layer and configured to carry medicament includes:

a first chamber configured to carry a prodrug, and a second chamber configured to carry an activating enzyme of the prodrug.

16. The final dosage form of claim 1, further comprising:

an indicator element configured to indicate an exposure of the release element to the stimulus.

17. The final dosage form of claim 16, wherein the indicator element configured to indicate an exposure of the release element to the stimulus includes:

an indicator element configured to make an optically-detectable change in response to an exposure of the release element to the stimulus.

18. The final dosage form of claim 16, wherein the indicator element configured to indicate an exposure of the release element to the stimulus includes:

an indicator element configured to optically indicate an exposure of the release element to the stimulus, the indicator element including at least one of 4-Keto-bacteriorhodopsin films, cinnamylidene acetyl chloride, α

-methylcinnamylidene acetyl chloride, α

,γ

-dimethylcinnamylidene acetyl chloride, α

-phenylcinnamylidene acetyl chloride, α

-phenoxycinnamylidene acetyl chloride, and cyanocinnamylidene acetyl chloride, leuco dye-serum albumin albumin complexes, azo dyes, and poly(ethylene glycol).

19. The final dosage form of claim 16, wherein the indicator element configured to indicate an exposure of the release element to the stimulus includes:

a substance configured to electronically indicate an exposure of the release element to the stimulus.

20. The final dosage form of claim 16, wherein the indicator element configured to indicate an exposure of the release element to the stimulus includes:

a substance having a property that makes an electronically-detectable change in response to an exposure of the release element to the stimulus.

21. The final dosage form of claim 16, wherein the indicator element configured to indicate an exposure of the release element to the stimulus includes:

a substance having a property that makes an ultrasonically-detectable change in response to an exposure of the release element to the stimulus.

22. The final dosage form of claim 16, wherein the indicator element configured to electronically indicate an exposure of the release element to the stimulus includes:

an indicator element configured to electronically indicate an exposure of the release element to the stimulus by at least one of dielectric, a conductivity, or ultrasonic profile responsive to an exposure of the release element to the stimulus.